While there are no pharmacokinetic data on the interactions between sirolimus and statins, it is certainly feasible that interactions could occur and result in tissue injury. In addition to the above case, the authors reference a case of rhabdomyolysis in a liver transplant recipient on sirolimus, tacrolimus and simvastatin [4]. Additionally, in a series of cardiac transplant patients on statin therapy who were transitioned from cyclosporine to sirolimus, there was a statistically significant doubling of myopathy events after the switch. Of note, most of the events were asymptomatic creatinine kinase elevations, and most occurred in the group of patients using pravastatin [5].
Higher peritoneal protein clearance on initiating PD has been shown to be associated with peripheral artery disease, being hence suggested as a new marker of systemic endothelial dysfunction [3] . In addition, peritoneal protein clearance was higher in high SSMT patients [3] . Inflammation may alter the peritoneal structure, resulting in functional changes such as increased SSMT, which has been associated with increased mortality risk [4] . One could speculate that impaired endothelial function might be the pathophysiological mechanism underlining the abnormal peritoneal function and increased mortality rate.
As we are not aware of other studies associating SSMT with endothelial function, we question whether Choi and colleagues have examined peritoneal function on their study patients and what sort of correlation they found between FMD and SSMT. We wonder if they were able to demonstrate any association between peritoneal transport, endothelial function and heightened inflammation in patients in the higher SSMT categories.
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